Dichloroacetic acid (DCA) synergizes with the SIRT2 inhibitor Sirtinol and AGK2 to enhance anti-tumor efficacy in non-small cell lung cancer

References

• Imai S, Armstrong CM, Kaeberlein M. Guarente L Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 2000;403(6771):795–800. doi:10.1038/35001622.
   PubMed Web of Science ®Google Scholar
• Wang Yp, Zhou Ls, Zhao Yz, Wang Sw, Chen Ll, Liu Lx, Ling Zq, Hu Fj, Sun Yp, Zhang Jy et al. Regulation of G6PD acetylation by SIRT2 and KAT9 modulates NADPH homeostasis and cell survival during oxidative stress. EMBO J. 2014;33(12):1304–1320. doi:10.1002/embj.201387224.
   PubMed Web of Science ®Google Scholar
• Xu Y, Li F, Lv L, Li T, Zhou X, Deng CX, Guan KL, Lei QY. Xiong Y Oxidative stress activates SIRT2 to deacetylate and stimulate phosphoglycerate mutase. Cancer Res. 2014;74(13):3630–3642. doi:10.1158/0008-5472.CAN-13-3615.
   PubMed Web of Science ®Google Scholar
• Wang F, Nguyen M, Qin FX. Tong Q SIRT2 deacetylates FOXO3a in response to oxidative stress and caloric restriction. Aging Cell. 2007;6(4):505–514. doi:10.1111/j.1474-9726.2007.00304.x.
   PubMed Web of Science ®Google Scholar
• Zhao D, Zou SW, Liu Y, Zhou X, Mo Y, Wang P, Xu YH, Dong B, Xiong Y, Lei QY, et al. Lysine-5 acetylation negatively regulates lactate dehydrogenase A and is decreased in pancreatic cancer. Cancer Cell. 2013;23(4):464–476. doi:10.1016/j.ccr.2013.02.005.
   PubMed Web of Science ®Google Scholar
• Rumpf T, Schiedel M, Karaman B, Roessler C, North BJ, Lehotzky A, Olah J, Ladwein KI, Schmidtkunz K, Gajer M, et al. 2015; Selective Sirt2 inhibition by ligand-induced rearrangement of the active site. Nat Commun. 6:6263. doi:10.1038/ncomms7263.
   PubMed Web of Science ®Google Scholar
• Jing H, Hu J, He B, Negron Abril YL, Stupinski J, Weiser K, Carbonaro M, Chiang YL, Southard T, Giannakakou P, et al. A SIRT2-Selective inhibitor promotes c-Myc oncoprotein degradation and exhibits broad anticancer activity. Cancer Cell. 2016;29(5):767–768. doi:10.1016/j.ccell.2016.04.005.
   PubMed Web of Science ®Google Scholar
• Grozinger CM, Chao ED, Blackwell HE, Moazed D. Schreiber Sl Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J Biol Chem. 2001;276(42):38837–38843. doi:10.1074/jbc.M106779200.
   PubMed Web of Science ®Google Scholar
• Outeiro TF, Kontopoulos E, Altmann SM, Kufareva I, Strathearn KE, Amore AM, Volk CB, Maxwell MM, Rochet JC, McLean PJ, et al. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson’s disease. Science. 2007;317(5837):516–519. doi:10.1126/science.1143780.
   PubMed Web of Science ®Google Scholar
• Cheon MG, Kim W, Choi M, Je: Ak-1 K. a specific SIRT2 inhibitor, induces cell cycle arrest by downregulating Snail in HCT116 human colon carcinoma cells. Cancer Lett. 2015;356(2 Pt B):637–645. doi:10.1016/j.canlet.2014.10.012.
   PubMed Web of Science ®Google Scholar
• Zhao D, Mo Y, Li MT, Zou SW, Cheng ZL, Sun YP, Xiong Y, Guan KL, Qy L. NOTCH-induced aldehyde dehydrogenase 1A1 deacetylation promotes breast cancer stem cells. J Clin Invest. 2014;124(12):5453–5465. doi:10.1172/JCI76611.
   PubMed Web of Science ®Google Scholar
• Singh S, Kumar PU, Thakur S, Kiran S, Sen B, Sharma S, Rao VV, Poongothai AR. Ramakrishna G Expression/localization patterns of sirtuins (SIRT1, SIRT2, and SIRT7) during progression of cervical cancer and effects of sirtuin inhibitors on growth of cervical cancer cells. Tumour Biol. 2015;36(8):6159–6171. doi:10.1007/s13277-015-3300-y.
   PubMedGoogle Scholar
• Wang J, Kim TH, Ahn MY, Lee J, Jung JH, Choi WS, Lee BM, Yoon KS, Yoon S. Kim HS: sirtinol, a class III HDAC inhibitor, induces apoptotic and autophagic cell death in MCF-7 human breast cancer cells. Int J Oncol. 2012;41(3):1101–1109. doi:10.3892/ijo.2012.1534.
   PubMed Web of Science ®Google Scholar
• Peck B, Chen CY, Ho KK, Di Fruscia P, Myatt SS, Coombes RC, Fuchter MJ, Hsiao CD. Lam Ew SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2. Mol Cancer Ther. 2010;9(4):844–855. doi:10.1158/1535-7163.MCT-09-0971.
   PubMed Web of Science ®Google Scholar
• Ota H, Tokunaga E, Chang K, Hikasa M, Iijima K, Eto M, Kozaki K, Akishita M, Ouchi Y. Kaneki M Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene. 2006;25(2):176–185. doi:10.1038/sj.onc.1209049.
   PubMed Web of Science ®Google Scholar
• Jin KL, Park JY, Noh EJ, Hoe KL, Lee JH, Kim JH. Nam Jh The effect of combined treatment with cisplatin and histone deacetylase inhibitors on HeLa cells. J Gynecol Oncol. 2010;21(4):262–268. doi:10.3802/jgo.2010.21.4.262.
   PubMed Web of Science ®Google Scholar
• Luthi-Carter R, Taylor DM, Pallos J, Lambert E, Amore A, Parker A, Moffitt H, Smith DL, Runne H, Gokce O, et al. SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proc Natl Acad Sci U S A. 2010;107(17):7927–7932. doi:10.1073/pnas.1002924107.
   PubMed Web of Science ®Google Scholar
• Kim HW, Kim SA. Ahn Sg Sirtuin inhibitors, EX527 and AGK2, suppress cell migration by inhibiting HSF1 protein stability. Oncol Rep. 2016;35(1):235–242. doi:10.3892/or.2015.4381.
   PubMed Web of Science ®Google Scholar
• He X, Nie H, Hong Y, Sheng C, Xia W. Ying W SIRT2 activity is required for the survival of C6 glioma cells. Biochem Biophys Res Commun. 2012;417(1):468–472. doi:10.1016/j.bbrc.2011.11.141.
   PubMed Web of Science ®Google Scholar
• Webster RM. Combination therapies in oncology. Nat Rev Drug Discov. 2016;15(2):81–82. doi:10.1038/nrd.2016.3.
   PubMed Web of Science ®Google Scholar
• Grbesa I, Pajares MJ, Martinez-Terroba E, Agorreta J, Mikecin AM, Larrayoz M, Idoate MA, Gall-Troselj K, Pio R. Montuenga Lm Expression of sirtuin 1 and 2 is associated with poor prognosis in non-small cell lung cancer patients. PLoS One. 2015;10(4):e0124670. doi:10.1371/journal.pone.0124670.
   PubMed Web of Science ®Google Scholar
• Matsushita N, Takami Y, Kimura M, Tachiiri S, Ishiai M, Nakayama T. Takata M Role of NAD-dependent deacetylases SIRT1 and SIRT2 in radiation and cisplatin-induced cell death in vertebrate cells. Genes Cells. 2005;10(4):321–332. doi:10.1111/j.1365-2443.2005.00836.x.
   PubMed Web of Science ®Google Scholar
• Hoffmann G, Breitenbucher F, Schuler M. Ehrenhofer-Murray Ae A novel sirtuin 2 (SIRT2) inhibitor with p53-dependent pro-apoptotic activity in non-small cell lung cancer. J Biol Chem. 2014;289(8):5208–5216. doi:10.1074/jbc.M113.487736.
   PubMed Web of Science ®Google Scholar
• Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621–681. doi:10.1124/pr.58.3.10.
   PubMed Web of Science ®Google Scholar
• Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440–446. doi:10.1158/0008-5472.CAN-09-1947.
   PubMed Web of Science ®Google Scholar
• Vander Heiden MG, Cantley LC. Thompson Cb Understanding the warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–1033. doi:10.1126/science.1160809.
   PubMed Web of Science ®Google Scholar
• Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, Lee CT, Lopaschuk GD, Puttagunta L, Harry G, et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell. 2007;11(1):37–51. doi:10.1016/j.ccr.2006.10.020.
   PubMed Web of Science ®Google Scholar
• Jia J, Zhu F, Ma X, Cao Z, Li Y. Chen Yz Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov. 2009;8(2):111–128. doi:10.1038/nrd2683.
   PubMed Web of Science ®Google Scholar
• Linn TC, Pettit FH. Reed Lj Alpha-keto acid dehydrogenase complexes. X. Regulation of the activity of the pyruvate dehydrogenase complex from beef kidney mitochondria by phosphorylation and dephosphorylation. Proc Natl Acad Sci U S A. 1969;62(1):234–241.
   PubMed Web of Science ®Google Scholar
• Jing E, O’Neill BT, Rardin MJ, Kleinridders A, Ilkeyeva OR, Ussar S, Bain JR, Lee KY, Verdin EM, Newgard CB, et al. Sirt3 regulates metabolic flexibility of skeletal muscle through reversible enzymatic deacetylation. Diabetes. 2013;62(10):3404–3417. doi:10.2337/db12-1650.
   PubMed Web of Science ®Google Scholar
• Faubert B, Boily G, Izreig S, Griss T, Samborska B, Dong Z, Dupuy F, Chambers C, Fuerth BJ, Viollet B, et al. AMPK is a negative regulator of the warburg effect and suppresses tumor growth in vivo. Cell Metab. 2013;17(1):113–124. doi:10.1016/j.cmet.2012.12.001.
   PubMed Web of Science ®Google Scholar
• Mungai PT, Waypa GB, Jairaman A, Prakriya M, Dokic D, Ball MK. Schumacker Pt Hypoxia triggers AMPK activation through reactive oxygen species-mediated activation of calcium release-activated calcium channels. Mol Cell Biol. 2011;31(17):3531–3545. doi:10.1128/MCB.05124-11.
   PubMed Web of Science ®Google Scholar
• Gomes P, Outeiro TF. Cavadas C Emerging role of sirtuin 2 in the regulation of mammalian metabolism. Trends Pharmacol Sci. 2015;36(11):756–768. doi:10.1016/j.tips.2015.08.001.
   PubMed Web of Science ®Google Scholar
• Park SH, Ozden O, Liu G, Song HY, Zhu Y, Yan Y, Zou X, Kang HJ, Jiang H, Principe DR, et al. SIRT2-mediated deacetylation and tetramerization of pyruvate kinase directs glycolysis and tumor growth. Cancer Res. 2016;76(13):3802–3812. doi:10.1158/0008-5472.CAN-15-2498.
   PubMed Web of Science ®Google Scholar
• Cha Y, Han MJ, Cha HJ, Zoldan J, Burkart A, Jung JH, Jang Y, Kim CH, Jeong HC, Kim BG, et al. Metabolic control of primed human pluripotent stem cell fate and function by the miR-200c-SIRT2 axis. Nat Cell Biol. 2017;19(5):445–456. doi:10.1038/ncb3517.
   PubMed Web of Science ®Google Scholar
• Tsusaka T, Guo T, Yagura T, Inoue T, Yokode M, Inagaki N. Kondoh H Deacetylation of phosphoglycerate mutase in its distinct central region by SIRT2 down-regulates its enzymatic activity. Genes Cells. 2014;19(10):766–777. doi:10.1111/gtc.12176.
   PubMed Web of Science ®Google Scholar
• Fan J, Shan C, Kang HB, Elf S, Xie J, Tucker M, Gu TL, Aguiar M, Lonning S, Chen H, et al. Tyr phosphorylation of PDP1 toggles recruitment between ACAT1 and SIRT3 to regulate the pyruvate dehydrogenase complex. Mol Cell. 2014;53(4):534–548. doi:10.1016/j.molcel.2013.12.026.
   PubMed Web of Science ®Google Scholar
• Kim I. He Yy 2013; Targeting the AMP-activated protein kinase for cancer prevention and therapy. Front Oncol. 3:175. doi:10.3389/fonc.2013.00175.
   PubMedGoogle Scholar
• Dugan LL, You YH, Ali SS, Diamond-Stanic M, Miyamoto S, DeCleves AE, Andreyev A, Quach T, Ly S, Shekhtman G, et al. AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function. J Clin Invest. 2013;123(11):4888–4899. doi:10.1172/JCI66218.
   PubMed Web of Science ®Google Scholar
• Imamura K, Ogura T, Kishimoto A, Kaminishi M, Esumi H. Cell cycle regulation via p53 phosphorylation by a 5ʹ-AMP activated protein kinase activator, 5-aminoimidazole- 4-carboxamide-1-beta-D-ribofuranoside, in a human hepatocellular carcinoma cell line. Biochem Biophys Res Commun. 2001;287(2):562–567. doi:10.1006/bbrc.2001.5627.
   PubMed Web of Science ®Google Scholar
• Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, Birnbaum MJ, Cb T. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell. 2005;18(3):283–293. doi:10.1016/j.molcel.2005.03.027.
   PubMed Web of Science ®Google Scholar
• Liang J, Shao Sh, Xu Zx, Hennessy B, Ding Z, Larrea M, Kondo S, Dumont Dj, Gutterman Ju, Walker Cl et al. The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol. 2007;9(2):218–224. doi:10.1038/ncb1537.
   PubMed Web of Science ®Google Scholar